From Diarylsulfides to Diarylamines: New Ebola Virus Entry Inhibitors with Improved Metabolic Stability

The persistence of current outbreaks of Ebola virus (EBOV) disease and challenges in the production and administration of approved vaccines and treatments highlight the continuous exploration of new therapeutic alternatives. In this context, this work focuses on optimizing diarylsulfide hits previously identified as EBOV entry inhibitors. Structural modifications resulted in diarylamine derivatives, with confirmed antiviral activity against replicative EBOV and significantly improved metabolic stability compared to diarylsulfides. Using different techniques, the EBOV glycoprotein (EBOV-GP) was identified as the target of these compounds. Residue Y517<sub>GP2</sub> is critical for biological activity, while T519<sub>GP2</sub>, E100<sub>GP1</sub>, and D522<sub>GP2</sub> also contribute to ligand binding. Furthermore, the binding of the derivatives to EBOV-GP has been shown to destabilize the complex with the virus receptor NPC1. In short, a new family of diarylsulfides and diarylamines with antiviral activity against EBOV has been developed, and their mechanism of action has been deciphered, paving the way for future pharmaceutical development.

Authors

Institutions

Publication Details

Journal
Journal of Medicinal Chemistry
Published
2025-05-17
DOI
https://doi.org/10.1021/acs.jmedchem.5c00615
Citations
2
Primary Topic
Viral Infections and Outbreaks Research
Type
article
Field-Weighted Citation Impact
2.79

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

From Diarylsulfides to Diarylamines: New Ebola Virus Entry Inhibitors with Improved Metabolic Stability

Fátima Lasala, Alfonso García‐Rubia, Marcos Morales-Tenorio, Michelle Heung et al.
2 citations
Journal of Medicinal Chemistry
Viral Infections and Outbreaks Research
2.79
article

From Diarylsulfides to Diarylamines: New Ebola Virus Entry Inhibitors with Improved Metabolic Stability

Fátima Lasala, Alfonso García‐Rubia, Marcos Morales-Tenorio, Michelle Heung, Ángeles Canales, Covadonga Alonso, Ana Martı́nez, Rafaël Delgado, Catherine Olal, Carmen Gil, César Muñoz‐Fontela, Elnaz Aledavood, Beatriz Escudero-Pérez, Paola Oquist
article en
2 citations

Abstract

The persistence of current outbreaks of Ebola virus (EBOV) disease and challenges in the production and administration of approved vaccines and treatments highlight the continuous exploration of new therapeutic alternatives. In this context, this work focuses on optimizing diarylsulfide hits previously identified as EBOV entry inhibitors. Structural modifications resulted in diarylamine derivatives, with confirmed antiviral activity against replicative EBOV and significantly improved metabolic stability compared to diarylsulfides. Using different techniques, the EBOV glycoprotein (EBOV-GP) was identified as the target of these compounds. Residue Y517<sub>GP2</sub> is critical for biological activity, while T519<sub>GP2</sub>, E100<sub>GP1</sub>, and D522<sub>GP2</sub> also contribute to ligand binding. Furthermore, the binding of the derivatives to EBOV-GP has been shown to destabilize the complex with the virus receptor NPC1. In short, a new family of diarylsulfides and diarylamines with antiviral activity against EBOV has been developed, and their mechanism of action has been deciphered, paving the way for future pharmaceutical development.

Journal of Medicinal ChemistryVol. 68(11)
Universidad Complutense de Madrid (ES), Instituto de Salud Carlos III (ES), Research Institute Hospital 12 de Octubre (ES), Biomedical Research Networking Center on Neurodegenerative Diseases (ES), Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria (ES), Centro de Investigación Biomédica en Red (ES), Centro de Investigaciones Biológicas Margarita Salas (ES), Indiana University School of Medicine, Bernhard Nocht Institute for Tropical Medicine (DE)
“la Caixa” Foundation, Ministerio de Ciencia, Innovación y Universidades, European Commission, Horizon 2020 Framework Programme, Consejo Superior de Investigaciones Científicas, Instituto de Salud Carlos III, European Regional Development Fund, Agencia Estatal de Investigación
Zero hunger
Openalex Percentile: Top 11%
Viral Infections and Outbreaks Research
2.79
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.